At DermASAP, we are continually exploring the latest in dermatologic therapeutics and remain fully engaged in clinical research. This allows us to offer our patients, on occasion, cutting edge therapies before they are available to the general population.
If you would like to learn more about these study opportunities, please contact us at studies@dermASAP.com. Patients enrolled in clinical trials often receive regular compensation for their time and efforts.
Quincy, MA Office (617) 934-0024
Plymouth, MA Office (508) 659-0777
PLEASE COMPLETE THIS FORM TO PARTICIPATE IN OUR CLINICAL TRIALS
Receive Specials & Promos
Description: A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
To be eligible for this registry, patients must meet all of the following criteria:
Have a diagnosis of psoriasis.
Are candidates for or are currently receiving conventional systemic agents (eg, MTX, acitretin, cyclosporine, fumarates, or systemic PUVA) or biologic therapy for psoriasis including those with chronic severe (extensive and/or disabling) plaque psoriasis who may be treated with Remicade or those with moderate to severe plaque psoriasis who may be treated with Stelara.
Have the ability to understand and sign an informed consent form.
Are male or female and at least 18 years of age.
Are willing to participate in regular follow-up visits.
Patients meeting any of the following criteria may not be enrolled in the registry:
Refuse to consent or are unwilling to respond to requests for long-term information within the required timeframe.
Are participating in an interventional clinical trial with an investigational agent (ie, non-marketed agent) or in a Johnson & Johnson-sponsored (eg, COBI-sponsored) interventional clinical trial.
Description: The primary objective of the Corona Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists.
The subject has psoriasis diagnosed by a dermatologist
The subject is at least 18 years of age or older (age 18 years)
The subject has started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments for psoriasis and non-biologic treatments (methotrexate, cyclosporine, or apremilast only) are allowed.
The subject is unable or unwilling to provide informed consent to participate in the registry.
Description: Harvesting of RNA-Containing Biological Material from Skin Cancer, Skin Cancer Precursors and Other Dermatologcal Conditions Via DermTechts Non-Invasive Adhesive Skin Sample Collection Kit.
Subject is at least 18 years of age
Presents with testable normal skin and for at least one skin lesion of interest
If there are multiple lesions to be harvested, they must be at least 4 mm apart
The subject is willing to follow standard of care procedures described by the investigator and/or sub-investigator
Subject is willing to provide informed consent to participate in this study
Subject is willing to follow all study procedures outlined in the protocol
Subject has generalized skin disorders that may interfere with the lesion/area to be harvested
Subject has a lesion for patch harvesting that was previously biopsied— such a lesion is to be excluded
The lesion is on the palms, on mucosal surfaces, or another area where harvesting of biological material via DermTech’s adhesive patch cannot be performed
Subject has an allergy to tape or latex rubber
Subject is currently participating, or has participated in the 30 days prior to this study, in an investigational (OTC, RX or device) study 6.
Subject with other abnormal clinical findings which the investigator feels may put the Subject at undue risk or may interfere with the study results
Description: Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study (MMAPPS)
Men and women age 18-80 with moderate to severe psoriasis (with or without arthritis) about to be initiated on etanercept therapy based on clinical criteria
MAJOR EXCLUSION CRITERIA
Pregnancy or breastfeeding
History of acute coronary syndromeistentingisurgery
History of significant autoimmune/inflammatory disease other than psoriasis
Contrast dye allergy
Observational Post-Marketing Safety Surveillance Registry of Enbrel ® (etanercept) for the Treatment of Psoriasis (OBSERVE-5 —)
ESPRIT is an international, multi-center, observational registry that will evaluate the long-term safety and effectiveness of Humira® (adalimumab) as used in routine clinical practice in adult patients with moderate to severe chronic plaque psoriasis (CPP) who are candidates for systemic therapy or phototherapy.
EPIC — Evaluating EpiCeram Emulsion® in the Clinic when Used as Monotherapy for Atopic Dermatitis
A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis.
SOLO 1, SOLO 2
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1)
Assessment and Tracking of Long-term Alefacept (LFA-3/IgG I Fusion Protein) Safety (ATLAS)